Dr. Zorn has more than 27 years drug discovery, drug development experience across a broad range of neuro and psychiatric disorders and across the whole value chain for drug discovery and development. Prior to his role as President and CEO of MindImmune, Dr. Zorn was EVP and head of Neuroscience Research for Lundbeck’s Research Site in the US. Prior to Lundbeck, Dr. Zorn was with Pfizer Global Research and Development for nearly 20 years. While there, Zorn became Pfizer’s first global head of Neuroscience Research, was co-architect of what became the company’s overall neuroscience area strategy, and co-led the 2nd largest and among the most productive therapeutic areas at Pfizer. Dr. Zorn received a BS degree in Chemistry from Lafayette College, and MS and Ph.D. degrees in Neuropharmacology from the University of Texas. Subsequently he did postdoctoral research studies at the Rockefeller University in the lab of Paul Greengard (Nobel Laureate).
Speaking In
[Available On-Demand]
MindImmune is a drug discovery venture focused on neuroinflammation, targeting Alzheimer’s as lead…